Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of drugs to treat acute respiratory distress syndrome. Its main drug candidates include Traumakine and Bex. The company was founded by Juho Markku Jalkanen, Sirpa Tuulikki Jalkanen, Matti Esa Manner, Juha Veikko Peltola, Marko Salmi, Katriina Peltola and Maija-Leena Hollmen, and Markku Tapani Jalkanen in 2003 and is headquartered in Turku, Finland.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company